EUVIMEDEUVIMED entdecken
Crossref

Transfusion‐Associated Graft‐Versus‐Host Disease in Pediatric Patients: Clinical Features and Outcomes

Isabel Araiza-Atanacio, Marimar Sáez-de-Ocariz, Luz Orozco-Covarrubias iD

Pediatric Dermatology · 2025

DOI: 10.1111/pde.15812 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Dermatology, 2025. Verfasst von Isabel Araiza-Atanacio und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Instituto Nacional de Pediatría, Mexico City, Mexico. Hauptthemen laut MEDLINE: Graft vs Host Disease, Transfusion Reaction. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Transfusion‐associated graft‐versus‐host disease (TA‐GVHD) is a rare, usually fatal complication of blood transfusion.

Objective

To describe the characteristics of TA‐GVHD in children.

Methods

The clinical records of pediatric patients diagnosed with TA‐GVHD between January 2007 and December 2021 were reviewed.

Results

We analyzed 94 clinical records of pediatric patients (0–18 years) with a diagnosis of GVHD, of whom 6 (6.38%) were associated with TA‐GVHD; both genders being equally affected. The median age at diagnosis of the underlying disorder was 9 years, 1 month (range 2 months–15 years, 3 months); the median age at diagnosis of TA‐GVHD was 9 years, 5.5 months (range 1 year, 7 months–15 years, 7 months). There were 27 grafts; 8 were irradiated and 12 were filtered. All patients presented with Stage 3 cutaneous TA‐GVHD and histopathological Grade 2. All cases corresponded to classic acute TA‐GVHD with global clinical Grade I–II. Mortality rate was 67%. The median follow‐up of our patients was 2 years and 2 months (range 4 months–3 years, 4 months).

Conclusions

TA‐GVHD, although less frequently encountered than in previous years, is still a concern. Early suspicion of TA‐GVHD is mandatory due to its high mortality rates and rapid progression. Prevention by using irradiated blood products is the sole effective measure against this condition. Failing to identify and preempt TA‐GVHD not only jeopardizes patient survival but also underscores the critical importance of vigilant monitoring and proactive intervention in at‐risk patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseaseTransfusion ReactionHumansChildMaleAdolescentFemaleChild, PreschoolInfantRetrospective StudiesInfant, Newborn

Stichwörter der Autor:innen

GVHDblood products transfusionchildren

Autor:innen und Institutionen

  • Dermatology Department, Instituto Nacional de Pediatría, Mexico City, Mexico.

ORCID-Profile: Luz Orozco-Covarrubias

Zitieren

APA

Araiza-Atanacio, I., Sáez-de-Ocariz, M., & Orozco-Covarrubias, L. (2025). Transfusion‐Associated Graft‐Versus‐Host Disease in Pediatric Patients: Clinical Features and Outcomes. Pediatric Dermatology. https://doi.org/10.1111/pde.15812

Vancouver

Araiza-Atanacio I, Sáez-de-Ocariz M, Orozco-Covarrubias L. Transfusion‐Associated Graft‐Versus‐Host Disease in Pediatric Patients: Clinical Features and Outcomes. Pediatric Dermatology. 2025. doi:10.1111/pde.15812

BibTeX
@article{AraizaAtanacio2025,
  author = {Araiza-Atanacio, Isabel and Sáez-de-Ocariz, Marimar and Orozco-Covarrubias, Luz},
  title = {Transfusion‐Associated Graft‐Versus‐Host Disease in Pediatric Patients: Clinical Features and Outcomes},
  journal = {Pediatric Dermatology},
  year = {2025},
  doi = {10.1111/pde.15812}
}
Kostenlos starten →